Cadila to Launch its Cadalimab (biosimilar, adalimumab) in India

 Cadila to Launch its Cadalimab (biosimilar, adalimumab) in India


  • Cadalimab will be available in 40mg/0.8ml as a pre-filled syringe and is targeted for the reduction in signs and symptoms of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Psoriasis
  • Additionally, Cadila has launched 3 more biosimilar products Bevaro, Ritucad, and NuPTH in the last 2 months
  • Adalimumab is a mAb and a disease-modifying antirheumatic drug that works by inactivating tumor necrosis factor-alpha (TNFα) recommended in the treatment of many diseases. In Feb 2020, Cadila concluded and cleared USFDA inspection

Click here to read full press release/ article | Ref: Cadila | Image: Signbox

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post